As a demonstration of Gck treatment responses in a whole-organism model, we showed that Gck activity can be modulated by the GKA Dorzagliatin to ameliorate hyperglycemia in pdx1 mutants, which occured without detectable activation of oxidative stress responses in liver or endocrine β-cells. The gene discussed is PDX1; the disease is Hyperglycemia.